The overall risk for incident retinopathy in patients who received hydroxychloroquine for 5 or more years was low but progressively increased with higher doses, according to researchers.
Hydroxychloroquine, which is recommended for patients with systemic lupus erythematosus and other inflammatory conditions, can have a “critical long-term adverse” impact: vision-threatening retinopathy, Ronald B. Melles, MD, an ophthalmologist affiliated with Kaiser Permanente Northern California, and colleagues wrote in Annals of Internal Medicine.
There has been limited research on the association